Skip to main content
H. Lundbeck A logo

H. Lundbeck A — Investor Relations & Filings

Ticker · HLUN ISIN · DK0061804770 LEI · 5493006R4KC2OI5D3470 CO Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country DK Denmark
Listing CO HLUN

About H. Lundbeck A

https://www.lundbeck.com/global

H. Lundbeck A/S is a global biopharmaceutical company specializing in brain diseases. The company is engaged in the research, development, manufacturing, and marketing of transformative therapies for a range of psychiatric and neurological disorders. Its portfolio and pipeline focus on conditions such as depression, mood disorders, and rare childhood-onset epilepsies. Lundbeck is dedicated to advancing neuroscience to improve the quality of life for individuals affected by central nervous system disorders.

Recent filings

Filing Released Lang Actions
Lundbeck raises financial guidance for 2026
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing an updated financial guidance for full-year 2026 revenue and adjusted EBITDA growth. It contains forward-looking statements and does not present actual past results (so it is not an Earnings Release or Interim/Quarterly Report), nor is it a detailed report itself (so not 10-K, IR, MDA, etc.). It is not soliciting votes, announcing dividends, legal actions, M&A or financing activity. There is no specific category for a guidance update, so this falls under the general Regulatory Filings (RNS) category as a miscellaneous disclosure under Market Abuse Regulation.
2026-05-12 English
Lundbeck raises financial guidance for 2026
Regulatory Filings Classification · 90% confidence The document is a corporate press release disclosing inside information under the EU Market Abuse Regulation, specifically updating 2026 financial guidance. It does not contain actual financial statements or full earnings data (so it is not an Interim/Quarterly Report or Earnings Release), nor does it announce a new report’s publication schedule or attach substantive financial tables (so it is not a Report Publication Announcement). It is a regulatory ad-hoc market disclosure, best classified under the general Regulatory Filings category (RNS).
2026-05-12 English
Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial
Regulatory Filings Classification · 95% confidence The document is a corporate press release from H. Lundbeck A/S announcing the completion of patient randomization for a Phase 3 clinical trial (MASCOT). It provides details on the trial, the drug (amlenetug), and forward-looking statements. While it contains information about company research, it does not fit into specific financial reporting categories like 10-K, IR, or ER. It is a general regulatory/corporate announcement. Per the 'Menu vs Meal' rule, although it mentions a PDF link at the end, the text itself is a standalone announcement of a clinical milestone, making it a general regulatory filing.
2026-03-09 English
Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial
Regulatory Filings Classification · 95% confidence The document is a corporate release from Lundbeck announcing the completion of patient randomization for a Phase 3 clinical trial (MASCOT). It provides details on the trial's progress, the drug's development status, and forward-looking statements regarding future results. As it is a general regulatory announcement regarding company operations and clinical trial milestones that does not fit into specific financial reporting categories like 10-K or ER, it is classified as a Regulatory Filing (RNS).
2026-03-09 English
Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by an executive (Lars Bang, Executive Vice President) of H. Lundbeck A/S. It follows the standard regulatory format for reporting insider dealings, including details of the person discharging managerial responsibilities, the nature of the transaction (sale of shares), price, volume, and date. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2026-02-18 English
Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by an executive (Lars Bang, Executive Vice President) of H. Lundbeck A/S. It follows the standard regulatory format for reporting insider dealings, including the name of the person, their position, the nature of the transaction (sale of shares), the price, volume, and date. This fits the definition of a 'Director's Dealing' (DIRS) filing.
2026-02-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.